• Tue news: 23andMe CEO no longer open to takeover. mRNA vaccines may boost cancer immunotherapy. BMS beats $6.4B lawsuit. CVS Health layoffs and potential breakup. JNJ abandoning proposed 340b plan. See more on our front page

Stock is looking great!

















The Cubist deal was among the worst in Pharma history. Naturally, we were part of it.
The historical lesson to be learned is the abysmal hiring of thousands of unethical, unmotivated, criminals into the Merck house. The sooner the whole apparatus is dismantled the better for my stock returns. Soup kitchens and breadlines to you all!
 








The historical lesson to be learned is the abysmal hiring of thousands of unethical, unmotivated, criminals into the Merck house. The sooner the whole apparatus is dismantled the better for my stock returns. Soup kitchens and breadlines to you all!

This has nothing to do with that, actually. You are an idiot.
 












Stock keeps running even as employee morale continues to plummet and the powers that be keep preaching the need to take things from us to "save" the company. I think it is time they start giving back to employees who have stayed loyal!

Be Well!

The captain and chief are dumping the stock. Go figure. Great timing as insiders they should know that EPS will be adjusted down. Great call.


01/15/2015 Adam H. Schechter
EVP & Pres-Global Human Health 74,200 Disposition at $62.48 per share. 4,636,016
01/15/2015 Adam H. Schechter
EVP & Pres-Global Human Health 5,000 Derivative/Non-derivative trans. at $34.47 per share. 172,350
01/15/2015 Adam H. Schechter
EVP & Pres-Global Human Health 19,200 Derivative/Non-derivative trans. at $35.09 per share. 673,728
01/15/2015 Adam H. Schechter
EVP & Pres-Global Human Health 50,000 Derivative/Non-derivative trans. at $44.19 per share. 2,209,500
01/09/2015 Kenneth C. Frazier
Chairman, President & CEO; Director 8,840 Disposition at $62.47 per share. 552,234
01/09/2015 Kenneth C. Frazier
Chairman, President & CEO; Director 3,541 Derivative/Non-derivative trans. at $31.84 per share. 112,745
01/09/2015 Kenneth C. Frazier
Chairman, President & CEO; Director 9,333 Derivative/Non-derivative trans. at $35.09 per share. 327,494
 




"Merck, the world's fourth-biggest drugmaker by revenue, predicted adjusted profit of $3.32 to $3.47 per share in 2015, well below the $3.50 analysts surveyed by FactSet were expecting. Merck said it expects full-year revenue in the range of $38.3 billion to $39.8 billion, while analysts were anticipating $40.46 billion."

"But revenue fell more than 7% year over year, missing Wall Street projections by $30 million, and Merck forecast that full-year 2015 revenue would fall more than 5% year over year."

Get real Ken. Now you are blaming a strong dollar for your problems? Try considering that Merck is a weak company run by an incompetent corner office. How many quarters of reduced market share and revenues does it take for investors to realize that you are not getting the job done? You have already admitted that it isn't happening in 2015 and we must wait until 2016 to see how your grand strategy plays out.
 




"Merck, the world's fourth-biggest drugmaker by revenue, predicted adjusted profit of $3.32 to $3.47 per share in 2015, well below the $3.50 analysts surveyed by FactSet were expecting. Merck said it expects full-year revenue in the range of $38.3 billion to $39.8 billion, while analysts were anticipating $40.46 billion."

"But revenue fell more than 7% year over year, missing Wall Street projections by $30 million, and Merck forecast that full-year 2015 revenue would fall more than 5% year over year."

Get real Ken. Now you are blaming a strong dollar for your problems? Try considering that Merck is a weak company run by an incompetent corner office. How many quarters of reduced market share and revenues does it take for investors to realize that you are not getting the job done? You have already admitted that it isn't happening in 2015 and we must wait until 2016 to see how your grand strategy plays out.

"Problems"? I have no stinking "problems". Did you see the previous post. I unloaded at 62+ per share. I guess I do have problems, tax problems.

Be Well,

KF
 




Today marks the beginning of what will be a steady decline in MRK over the next couple of years. The run up to $62 was completely unwarranted and quite obviously manufactured by our own illustrious management, who needed to unload their shares at the highest point possible. They should all be in jail. These scum suckers cash in on millions while tens of thousands were shown the door. It's enough to make you sick.
 








Today marks the beginning of what will be a steady decline in MRK over the next couple of years. The run up to $62 was completely unwarranted and quite obviously manufactured by our own illustrious management, who needed to unload their shares at the highest point possible. They should all be in jail. These scum suckers cash in on millions while tens of thousands were shown the door. It's enough to make you sick.

We are not at the beginning, we are in the middle of it. Today offers just another milestone metric in the steady decline of Merck. Revenues have been less than the previous year every year in the last 4 and are projected to do so again in 2015. Even so investors have pushed this stock up to levels not seen since 2001 and 63% of the stocks all time high in 2000. I for one never understand this disconnect between company and stock performance. Reality will eventually catch up.
 




The captain and chief are dumping the stock. Go figure. Great timing as insiders they should know that EPS will be adjusted down. Great call.


01/15/2015 Adam H. Schechter
EVP & Pres-Global Human Health 74,200 Disposition at $62.48 per share. 4,636,016
01/15/2015 Adam H. Schechter
EVP & Pres-Global Human Health 5,000 Derivative/Non-derivative trans. at $34.47 per share. 172,350
01/15/2015 Adam H. Schechter
EVP & Pres-Global Human Health 19,200 Derivative/Non-derivative trans. at $35.09 per share. 673,728
01/15/2015 Adam H. Schechter
EVP & Pres-Global Human Health 50,000 Derivative/Non-derivative trans. at $44.19 per share. 2,209,500
01/09/2015 Kenneth C. Frazier
Chairman, President & CEO; Director 8,840 Disposition at $62.47 per share. 552,234
01/09/2015 Kenneth C. Frazier
Chairman, President & CEO; Director 3,541 Derivative/Non-derivative trans. at $31.84 per share. 112,745
01/09/2015 Kenneth C. Frazier
Chairman, President & CEO; Director 9,333 Derivative/Non-derivative trans. at $35.09 per share. 327,494

A great days work! What have you envious turds done recently?
 








2014 banner year according to the man on stage this week. Future is bright, Januvia up 5% over last year and Belsomra could be a superb first in class winner by years end... Where's the love?
 












Similar threads

Replies
8
Views
3K
Merck
anonymous
Replies
1
Views
536
Merck
anonymous
Replies
10
Views
2K
Merck
anonymous